BioDlink International Co Ltd
01875
Company Profile
Business description
BioDlink International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families, as well as medical professionals. The company has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The company generates maximum revenues from Mainland China.
Contact
120 Changyang Street
Suzhou Industrial Park
Suzhou215024
CHNT: +86 51262965186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
604
Stocks News & Analysis
stocks
Are small caps finally back?
Does renewed investor interest point to a structural shift in the underperforming factor?
stocks
Chart of the Week: Modest earnings growth at odds with overvalued bank shares
The latest update from our Industry Pulse report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,329.10 | 50.90 | 0.55% |
| CAC 40 | 8,225.78 | 18.91 | 0.23% |
| DAX 40 | 24,207.79 | 56.66 | 0.23% |
| Dow JONES (US) | 46,734.61 | 144.20 | 0.31% |
| FTSE 100 | 9,578.57 | 63.57 | 0.67% |
| HKSE | 25,967.98 | 186.21 | 0.72% |
| NASDAQ | 22,941.80 | 201.40 | 0.89% |
| Nikkei 225 | 48,641.61 | 666.18 | -1.35% |
| NZX 50 Index | 13,377.10 | 70.66 | 0.53% |
| S&P 500 | 6,738.44 | 39.04 | 0.58% |
| S&P/ASX 200 | 9,032.80 | 46.60 | 0.52% |
| SSE Composite Index | 3,922.41 | 8.65 | 0.22% |